Company Description
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States.
The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets.
It develops MT-601, which is in Phase 1 trials for the treatment of lymphoma and pancreatic cancer; and MT-401-OTS, which is in a Phase 1 trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes.
The company was formerly known as TapImmune, Inc. and changed its name to Marker Therapeutics, Inc. in October 2018.
Marker Therapeutics, Inc. was founded in 1999 and is headquartered in Houston, Texas.
| Country | United States |
| Founded | 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Juan Vera |
Contact Details
Address: 2450 Holcombe Blvd, TMC Partners Office 1.311 Houston, Texas 77021 United States | |
| Phone | 713 400 6400 |
| Website | markertherapeutics.com |
Stock Details
| Ticker Symbol | MRKR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001094038 |
| CUSIP Number | 57055L107 |
| ISIN Number | US57055L2060 |
| Employer ID | 88-0277072 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Juan F. Vera M.D. | Co-Founder, Chief Executive Officer, President, Treasurer, Secretary and Director |
| Elizabeth Donnelly | Director of Administration |
| Dr. Maria-Bernadette Madel Ph.D. | Director of Corporate Operations and External Communications |
| Edmund Cheung | Vice President of Human Resources |
| Patricia Allison | Head of Clinical Operations |
| Mary Newman Ph.D. | Head of Regulatory Affairs |
| Dr. Robert Z. Florkiewicz Sr., Ph.D. | Senior Director of Molecular Biology and Virology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 20, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 20, 2026 | ARS | Filing |
| Mar 20, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 19, 2026 | 8-K | Current Report |
| Mar 18, 2026 | 10-K | Annual Report |
| Mar 10, 2026 | PRE 14A | Other preliminary proxy statements |
| Feb 9, 2026 | 8-K | Current Report |
| Nov 17, 2025 | SCHEDULE 13D/A | Filing |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 14, 2025 | 8-K | Current Report |